One concern with NK cell-based therapies is that long-term exposure to NKG2D ligands derived from tumor exosomes in TME leads to impaired cytotoxicity and reduced tumor immune surveillance [31,32,33]. The gene discussed is KLRK1; the disease is neoplasm.